Esokap-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing gastric emptying and increasing lower esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and efficacy. Esokap-D Capsule SR is indicated for patients requiring both acid suppression and prokinetic therapy, particularly in cases where delayed gastric emptying contributes to symptomatology. It should be used under medical supervision, considering potential contraindications such as hypersensitivity to components, and caution in patients with cardiac arrhythmias or hepatic impairment. Common adverse effects may include headache, dry mouth, and abdominal discomfort. Drug interactions should be evaluated prior to initiation. Esokap-D Capsule SR offers a synergistic approach to managing upper gastrointestinal symptoms by addressing both acid secretion and motility dysfunction.